Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth?

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Multi-institutional collaborations are crucial for studying rare diseases like soft tissue sarcomas.
• The efficacy of radiation therapy (RT) for superficial, high-grade soft tissue sarcomas of the trunk and extremity remains unclear.
• This study investigates RT's value using data from the US Sarcoma Collaborative (USSC) and the National Cancer Database (NCDB).

Purpose of the Study:

• To evaluate the impact of radiation therapy on outcomes for patients with superficial, high-grade soft tissue sarcomas.
• To compare findings between a specialized collaborative group (USSC) and a large national database (NCDB).

Main Methods:

• Analysis of adult patients with superficial truncal and extremity high-grade soft tissue sarcomas undergoing primary curative-intent resection.
• Inclusion of data from USSC (2000-2016) and NCDB (2004-2013).
• Application of propensity score matching to compare outcomes between patients who received RT and those who did not.

Main Results:

• In the USSC cohort, RT was not associated with improved locoregional recurrence-free survival (LRFS), overall survival (OS), or disease-specific survival (DSS).
• Propensity score matching in the USSC cohort confirmed no significant benefit from RT.
• In the NCDB cohort, RT was associated with improved 5-year OS (80% vs. 70%, p=0.02), but LRFS and DSS were not evaluable.

Conclusions:

• Collaborative research provides valuable data, but different datasets can yield conflicting results.
• USSC data suggests RT offers no benefit, while NCDB data indicates improved OS, contradicting existing randomized controlled trials.
• The findings underscore the limitations of database analysis for certain outcomes and emphasize the importance of randomized controlled trials in sarcoma treatment.